We see access to basic services (tied to potential US policy changes on drug pricing) as the next-biggest potential ESG ... We provide a platform for our authors to report on investments fairly, ...
This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential ... risks related to the pricing of the RNS System and availability of adequate ...
Voter anger over inflation helped propel Donald Trump to the White House, and now those voters want him to take action to ...
Johnson & Johnson launched a legal challenge against a federal health agency blocking the company’s quest to tighten the way ...
Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...
Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...
Optum Savings IQ™ enables automation of search and enrollment in financial assistance programs from all sources and helps to save patients more than $2,500 annually.
In its lawsuit, the company argued the U.S. Health Resources and Services Administration has wrongfully interpreted a federal ...
Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback